Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel
- 30 June 2009
- journal article
- Published by Elsevier BV in Lung Cancer
- Vol. 64 (3), 326-333
- https://doi.org/10.1016/j.lungcan.2008.09.002
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Class III β-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non–Small Cell Lung CancerCancer Research, 2007
- Excision repair cross‐complementation group 1 predicts progression‐free and overall survival in non‐small cell lung cancer patients treated with platinum‐based chemotherapyCancer Science, 2007
- Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β‐tubulinsInternational Journal of Cancer, 2007
- ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabineAnnals of Oncology, 2006
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant ChemotherapyNew England Journal of Medicine, 2006
- Determinants of chemosensitivity in gastric cancerCurrent Opinion in Pharmacology, 2006
- Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxelMolecular Cancer Therapeutics, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000